bcr-abl peptide vaccine

BIOLOGICAL2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, OHSU Knight Cancer Institute

Conditions

Leukemia

Phase 2

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

CompletedNCT00004052

Memorial Sloan Kettering Cancer CenterLeukemia

Start: 1999-03-31End: 2005-08-31Target: 24Updated: 2013-06-25

Vaccine Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

TerminatedNCT00428077

OHSU Knight Cancer InstituteLeukemia

Start: 2005-10-31End: 2009-04-30Updated: 2011-09-02